首页> 外国专利> Monocyclic Compounds, Pharmaceutical compositions containing them and their use as taquiquinina NK2 Receptor Antagonists in the treatment of depatologias where release of Tachykinin

Monocyclic Compounds, Pharmaceutical compositions containing them and their use as taquiquinina NK2 Receptor Antagonists in the treatment of depatologias where release of Tachykinin

机译:单环化合物,含有它们的药物组合物及其作为速喹奎纳NK2受体拮抗剂在治疗速激肽(其中释放速激肽)的治疗中的用途

摘要

The monocyclic compounds in general formula (1), in which: x1, X2, X3, x4, whether equal or different, constitute a group from: - conr -.-NRCO -, - CH2-NR-,-Nr-ch2-r is h, c1-3 tar, benzene; F and m, whether equal or different, are the selected numbers between 0, 1 and 2; R1 and R2, whether marine or different, constitute a group - (CH2) r-ar, R equals 0, 1, 2, AR is an aromatic group, selected from benzene, naflina, thiophosphor, benzothion, pyridine, quinine, indola, furan, 1. Benzofuran, tiazol, benzotiazol, imidazol, benzoimidazol can be replaced by up to two substitutes selected from c1-3 tar, halogenated tar, c1-3 tar, aminobenzene c2-4-alkyl, halogen, O H, NH2, CN, n6r7, donder6 and R7. No matter whether these substitutes are the same or not, they are h or c1-3 tar;R3 is a group selected from the following groups: ((CH2) r-ar1, R equals to 0, 1, 2, AR1 is an aromatic group, selected from benzene, naflina, thiophosphor, benzothion, pyridine, quinoline, indol, furan, benzofuran, tiazor, benzothion, imidazole, benzopidan, The most two substitutes selected from c1-3 tar and halogen tar, c1-3 tar and aminobenzene, halogen, O H, NH2, CN, nr6r7, wherein R6 and R7, whether equal or different, are h or c1-3; R5 is h; R4 is a group selected from: - n8r9: R8 is h or alkyl 1-3; r9 is sulfur, Tetrahydropyridine tetrahydrophenyl etherIt may be monomer or carbon dioxide in the atom, which is replaced by c1-3 tar, c1-3 acid solution, Sulfanilamide and thiomethane in N atom; or a group of (CH2) g-r10, where G is 1, 2, 3 and R10, calculated between morfolino, Furano and CN; Or R8 and R9, together with the associated N atoms, constitute a pipe, which may be replaced by c1-3, c1-3 ACIO or sulfomethane in a kind of susnitrogene; n (R11) CO (CH2) h-r12 in which R11 is h or c1-3 hydrocarbon; h is 0, 1, 2, 3; R12 sesesessessessessessione is between: morfolino and pirrolidino may be replaced by hydroxy or hydroxyethyl, piperidina May be affected by a hydrogen oxide compound or
机译:通式(1)中的单环化合物,其中:x1,X2,X3,x4相同或不同,构成以下基团:-conr -.- NRCO-,-CH2-NR-,-Nr-ch2- r是h,c1-3焦油,苯; F和m相等或不同,是介于0、1和2之间的所选数字; R1和R2,无论是海洋的还是不同的,构成一个基团-(CH2)r-ar,R等于0、1、2,AR是一个芳香族基团,选自苯,萘啶,硫代磷,苯并硫,吡啶,奎宁,吲哚,呋喃1.苯并呋喃,噻唑,苯并噻唑,咪唑,苯并咪唑最多可被两个取代基取代,这些取代基选自c1-3焦油,卤代焦油,c1-3焦油,氨基苯c2-4-烷基,卤素,OH,NH2,CN ,n6r7,donder6和R7。无论这些取代基是否相同,它们都是h或c1-3 tar; R3是选自以下基团的基团:((CH2)r-ar1,R等于0、1、2,AR1是芳族基团,选自苯,萘啶,硫代磷,苯并硫磷,吡啶,喹啉,吲哚,呋喃,苯并呋喃,噻唑,苯并硫磷,咪唑,苯并吡喃,最多两个取代基选自c1-3焦油和卤素焦油,c1-3焦油和氨基苯,卤素,OH,NH2,CN,nr6r7,其中R6和R7相同或不同,为h或c1-3; R5为h; R4为选自以下的基团:-n8r9:R8为h或烷基1- 3; r9是硫,四氢吡啶四氢苯基醚,它可以是原子中的单体或二氧化碳,被N原子中的c1-3焦油,c1-3酸溶液,磺胺和硫代甲烷取代;或(CH2)g- r10,其中G为1、2、3和R10,在morfolino,Furano和CN之间计算;或者R8和R9与相关的N原子一起构成管道,可以用c1-3,c1-3 ACIO代替Ø磺基甲烷中的一种亚硝基n(R11)CO(CH2)h-r12,其中R11是h或c1-3烃; h是0、1、2、3; R12介于:morfolino和pirrolidino可以被羟基或羟乙基,哌啶子基取代可能受氧化氢化合物或

著录项

  • 公开/公告号AR021751A1

    专利类型

  • 公开/公告日2002-08-07

    原文格式PDF

  • 申请/专利权人 MENARINI RICERCHE S.P.A;

    申请/专利号AR1999P103922

  • 发明设计人

    申请日1999-08-05

  • 分类号C07K5/023;C07K7/22;A61K38/07;A61P1/00;A61P11/00;

  • 国家 AR

  • 入库时间 2022-08-22 00:46:26

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号